Menu

Final Nail Hammered into NgAgo Coffin

The paper describing the gene-editing method is retracted.

Aug 3, 2017
Kerry Grens

ISTOCK, FSTOP123Following an editorial expression of concern last year, the authors of a study describing a gene-editing method have retracted their paper from Nature Biotechnology. They say that despite the efforts of numerous independent laboratories, their observations could not be replicated.

The editors of Nature Biotechnology praised the process. “[I]t is the wider research community that tests methods, identifies potential sources of error, validates reagents and optimizes assays,” they wrote in an editorial. “In this case, it took dozens of dedicated individuals to work through the details of the published protocol and produce well-documented and controlled refutation studies.”

The original study claimed to have found a competitor for CRISPR genome editing. NgAgo, an Argonaut protein from archaea, could precisely disrupt specified sequences in the human genome, Chunyu Han of Hebei University of Science and Technology in Shijiazhuang, China, and colleagues reported. But replication attempts failed.

“We are therefore retracting our initial report at this time to maintain the integrity of the scientific record,” Han’s team wrote in the retraction notice. “We nevertheless continue to investigate the reasons for this lack of reproducibility with the aim of providing an optimized protocol.”

See “Scientists Can’t Replicate Gene-Editing Method

As Nature points out, Danish biomedical company Novozymes paid an undisclosed amount of money to partner with Hebei. “Scientific research takes time and we’ll continue to look for any technological advances, NgAgo included, that can have a positive impact on our work,” Dongyi Chen, Novozymes’s press manager, tells Nature.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.